

# PHARMACY BENEFIT MANAGEMENT v3.1

## RISK MANAGEMENT

RM 1: Regulatory Compliance and Internal Controls

RM 1-1: Regulatory Compliance Management

RM 2: Regulatory Compliance

RM 2-1: Maintaining Compliance

RM 3: Information Systems

RM 3-1: Information Systems Management

RM 3-2: Systems Risk Assessment

RM 4: Business Continuity

RM 4-1: Business Continuity Plan

#### OPERATIONS AND INFRASTRUCTURE

**OPIN 1: Business Management** 

OPIN 1-1: Policy and Process Maintenance

OPIN 1-2: Delegation Management

OPIN 2: Staff Management

OPIN 2-1: Clinical Staff Credentialing

OPIN 2-2: Employment Screening

OPIN 2-3: Staff Training Programs

OPIN 2-4: Code of Ethical Conduct

OPIN 2-5: Employee Diversity, Equity and Inclusion

OPIN 3: Clinical Leadership

OPIN 3-1: Clinical Staff Leadership

# PERFORMANCE MONITORING AND IMPROVEMENT

PMI 1: Quality Management Scope

PMI 1-1: Quality Structure

PMI 2: Quality Data Collection and Evaluation
PMI 2-1: Data Collection and Evaluation

## CONSUMER PROTECTION AND EMPOWERMENT

CPE 1: Protection of Consumer Information

CPE 1-1: Privacy and Security of Consumer

Information

CPE 2: Consumer Safeguards and Communication

CPE 2-1: Consumer Diversity, Equity and Inclusion

CPE 2-2: Consumer Safety Protocols

CPE 2-3: Consumer Complaint Process

CPE 2-4: Health Literacy Promotion

CPE 2-5: Consumer Marketing and Communication

Safeguards

## PHARMACY AND THERAPEUTICS COMMITTEE

PBM-PT 1: Committee Members

PBM-PT 1-1: Membership

PBM-PT 1-2: Conflict of Interest

PBM-PT 1-3: Membership Exclusions

PBM-PT 2: Committee Meetings and Responsibilities

PBM-PT 2-1: Meetings

PBM-PT 2-2: Responsibilities



#### FORMULARY AND DRUG MANAGEMENT

PBM-FDM 1: Formulary Management

PBM-FDM 1-1: Formulary Management

PBM-FDM 2: Formulary Exceptions and Coverage

**Exclusions** 

PBM-FDM 2-1: Formulary Exceptions

PBM-FDM 2-2: Coverage Exclusions

PBM-FDM 3: Drug Utilization Management Program

PBM-FDM 3-1: Program Implementation

PBM-FDM 3-2: Initial Determination

PBM-FDM 3-3: Initial Determination Notifications

PBM-FDM 3-4: Lack of Information

PBM-FDM 3-5: Appeal Determinations

PBM-FDM 3-6: Appeal Determination Notifications

PBM-FDM 4: Drug Utilization Review Program

PBM-FDM 4-1: Drug Utilization Review

PBM-FDM 5: Adherence Program

PBM-FDM 5-1: Adherence Program Scope

PBM-FDM 6: Program Performance Reporting

PBM-FDM 6-1: Drug Utilization Management

**Program Reporting** 

PBM-FDM 6-2: Drug Utilization Review Program

Reporting

PBM-FDM 6-3: Adherence Program Reporting

# NETWORK MANAGEMENT

PBM-NM 1: Scope

PBM-NM 1-1: Scope of Services

PBM-NM 1-2: Electronic Requirements

PBM-NM 2: Pharmacy Network Participation

PBM-NM 2-1: Participation Agreement

PBM-NM 2-2: Network Participation Information

PBM-NM 3: Network Credentialing and Recredentialing

PBM-NM 3-1: Credentialing and Recredentialing

PBM-NM 4: Pharmacy Network Management

PBM-NM 4-1: Suspension and Termination

PBM-NM 5: Network Management Performance

PBM-NM 5-1: Access and Availability

PBM-NM 5-2: Network Pharmacy Satisfaction

## CLIENT RELATIONS

PBM-CR 1: Client Disclosures

PBM-CR 1-1: Client Disclosures

PBM-CR 2: Client Performance and Reporting

PBM-CR 2-1: Client Satisfaction PBM-CR 2-2: Client Reporting

## MEMBER SERVICES AND COMMUNICATION

PBM-MSC 1: Information and Support Services

PBM-MSC 1-1: Information & Support

PBM-MSC 1-2: Benefit Changes

PBM-MSC 1-3: Accommodating Diverse Populations

PBM-MSC 2: Measuring Complaints and Satisfaction

PBM-MSC 2-1: Member and Prescriber Complaints

PBM-MSC 2-2: Member and Prescriber Satisfaction

PBM-MSC 3: Communication Process and Monitoring

PBM-MSC 3-1: Telephone Performance

PBM-MSC 3-2: Non-Telephonic Communications

PBM-MSC 3-3: Clinical Communication Services

# REPORTING PERFORMANCE MEASURES TO URAC

RPT 1: Reporting Mandatory Performance Measures to URAC

RPT 1-1: Reporting Mandatory Performance

Measures to URAC

RPT 2: Reporting Exploratory Performance Measures to URAC

RPT 2-1: Reporting Exploratory Performance

Measures to URAC